Logo

Shionogi Presents Real-World Evidence of Fetroja (cefiderocol) for Treatment Resistant Bacterial Infections at IDWeek 2022

Share this
Shionogi Presents Real-World Evidence of Fetroja (cefiderocol) for Treatment Resistant Bacterial Infections at IDWeek 2022

Shionogi Presents Real-World Evidence of Fetroja (cefiderocol) for Treatment Resistant Bacterial Infections at IDWeek 2022

Shots:

  • The company reported the results from the (PROVE) retrospective study evaluating the real-world outcomes and safety of Fetroja in hospitalized patients with Gram-bacterial infections
  • The results showed that Fetroja achieved clinical cure in 63% of patients with Acinetobacter baumannii infections or Pseudomonas aeruginosa infections. In both Infections, 96% & 97% were resistant to carbapenems while the safety and tolerability results were consistent with the safety profile of Fetroja in clinical studies
  • 79% of patients were alive and 21% of patients died within 30 days of starting Fetroja (30-day all-cause mortality), 1 patient experienced a serious ADR. In an analysis of early use experience, incl. compassionate use where patients had limited treatment options, 80% of patients reported clinical cures for difficult-to-treat gram- inf.

Ref: Shionogi | Image: Shionogi

Click here to­ read the full press release 

Neha

Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions